{"drugs":["Orimune","Poliovirus Vaccine, Live"],"mono":{"0":{"id":"472680-s-0","title":"Generic Names","mono":"Poliovirus Vaccine, Live"},"1":{"id":"472680-s-1","title":"Dosing and Indications","sub":{"0":{"id":"472680-s-1-4","title":"Adult Dosing","mono":"<ul><li>routine production of oral poliovirus vaccine (OPV) has been discontinued in the United States; an emergency stockpile is maintained in the event of a poliovirus outbreak<\/li><li><b>Poliomyelitis, acute; Prophylaxis:<\/b> (mass vaccination for outbreak control) 0.5 mL ORALLY x 1 dose<\/li><\/ul>"},"1":{"id":"472680-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>not recommended in infants less than 6 weeks of age<\/li><li>routine production of oral poliovirus vaccine (OPV) has been discontinued in the United States; an emergency stockpile is maintained in the event of a poliovirus outbreak<\/li><li><b>Poliomyelitis, acute; Prophylaxis:<\/b> (mass vaccination for outbreak control) 0.5 mL ORALLY x 1 dose<\/li><\/ul>"},"3":{"id":"472680-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Poliomyelitis, acute; Prophylaxis<br\/>"}}},"3":{"id":"472680-s-3","title":"Contraindications\/Warnings","sub":[{"id":"472680-s-3-9","title":"Contraindications","mono":"<ul><li>fever or severe respiratory infection<\/li><li>hypersensitivity to vaccine components<\/li><li>immunodefiency disorders or altered immune systems<\/li><li>household contacts of immunodeficient individuals<\/li><li>severe viral infection (diarrhea, vomiting)<\/li><\/ul>"},{"id":"472680-s-3-10","title":"Precautions","mono":"<ul><li>concurrent administration of  cholera vaccine, typhoid vaccine, or plague vaccine<\/li><li>elderly patients<\/li><li>hypersensitivity to neomycin or streptomycin<\/li><li>IM injections, especially antibiotics, should be avoided for 30-60 days; increased risk of paralytic poliomyelitis<\/li><li>inadvertent OPV vaccine to household contact of immunosuppressed person; avoid close contact for 4-6 weeks after vaccination<\/li><li>pregnancy<\/li><\/ul>"},{"id":"472680-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"472680-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"472680-s-4","title":"Drug Interactions","sub":{"1":{"id":"472680-s-4-14","title":"Major","mono":"<ul><li>Aclarubicin (established)<\/li><li>Adalimumab (theoretical)<\/li><li>Aldesleukin (established)<\/li><li>Altretamine (established)<\/li><li>Amonafide (established)<\/li><li>Amsacrine (established)<\/li><li>Asparaginase (established)<\/li><li>Azacitidine (established)<\/li><li>Azathioprine (established)<\/li><li>Bleomycin (established)<\/li><li>Broxuridine (established)<\/li><li>Busulfan (established)<\/li><li>Capecitabine (established)<\/li><li>Carboplatin (established)<\/li><li>Carmustine (established)<\/li><li>Certolizumab Pegol (theoretical)<\/li><li>Chlorambucil (established)<\/li><li>Cisplatin (established)<\/li><li>Cladribine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Cyclosporine (theoretical)<\/li><li>Cytarabine (established)<\/li><li>Cytarabine Liposome (established)<\/li><li>Dacarbazine (established)<\/li><li>Dactinomycin (established)<\/li><li>Daunorubicin (established)<\/li><li>Daunorubicin Citrate Liposome (established)<\/li><li>Decitabine (established)<\/li><li>Docetaxel (established)<\/li><li>Doxifluridine (established)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Edatrexate (established)<\/li><li>Eflornithine (established)<\/li><li>Epirubicin (established)<\/li><li>Estramustine (established)<\/li><li>Etanercept (established)<\/li><li>Etoposide (established)<\/li><li>Everolimus (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Floxuridine (established)<\/li><li>Fludarabine (established)<\/li><li>Fluorouracil (established)<\/li><li>Fotemustine (established)<\/li><li>Gallium Nitrate (established)<\/li><li>Gemcitabine (established)<\/li><li>Golimumab (theoretical)<\/li><li>Hydroxyurea (established)<\/li><li>Idarubicin (established)<\/li><li>Ifosfamide (established)<\/li><li>Immune Globulin (probable)<\/li><li>Infliximab (theoretical)<\/li><li>Irinotecan (established)<\/li><li>Lomustine (established)<\/li><li>Mechlorethamine (established)<\/li><li>Melphalan (established)<\/li><li>Mercaptopurine (established)<\/li><li>Methotrexate (established)<\/li><li>Mitolactol (established)<\/li><li>Mitomycin (established)<\/li><li>Mitotane (established)<\/li><li>Mitoxantrone (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Oxaliplatin (established)<\/li><li>Paclitaxel (established)<\/li><li>Pegaspargase (established)<\/li><li>Pentostatin (established)<\/li><li>Pipobroman (established)<\/li><li>Pirarubicin (established)<\/li><li>Plicamycin (established)<\/li><li>Procarbazine (established)<\/li><li>Raltitrexed (established)<\/li><li>Rilonacept (theoretical)<\/li><li>Rituximab (established)<\/li><li>Secukinumab (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sirolimus (probable)<\/li><li>Streptozocin (established)<\/li><li>Tacrolimus (theoretical)<\/li><li>Teceleukin (established)<\/li><li>Tegafur (established)<\/li><li>Temsirolimus (theoretical)<\/li><li>Teniposide (established)<\/li><li>Thioguanine (established)<\/li><li>Thiotepa (established)<\/li><li>Topotecan (established)<\/li><li>Trabectedin (theoretical)<\/li><li>Treosulfan (established)<\/li><li>Trimetrexate (established)<\/li><li>Trofosfamide (established)<\/li><li>Uracil Mustard (established)<\/li><li>Ustekinumab (theoretical)<\/li><li>Vinblastine (established)<\/li><li>Vincristine (established)<\/li><li>Vincristine Sulfate Liposome (established)<\/li><li>Vindesine (established)<\/li><li>Vinorelbine (established)<\/li><\/ul>"},"2":{"id":"472680-s-4-15","title":"Moderate","mono":"<ul><li>Abatacept (probable)<\/li><li>Leflunomide (established)<\/li><\/ul>"}}},"5":{"id":"472680-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Other:<\/b>Fever<br\/><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Anaphylaxis (rare)<\/li><li><b>Neurologic:<\/b>Guillain-Barr  syndrome, Association with vaccine unlikely, Paralytic poliomyelitis, vaccine-associated, acute (rare)<\/li><\/ul>"},"6":{"id":"472680-s-6","title":"Drug Name Info","sub":{"0":{"id":"472680-s-6-17","title":"US Trade Names","mono":"Orimune<br\/>"},"2":{"id":"472680-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"472680-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"472680-s-7","title":"Mechanism Of Action","mono":"Systemic: OPV induces intestinal immunity against poliovirus reinfection, which explains its effectiveness in controlling the wild-type poliovirus circulation . In addition, OPV persists in the pharynx for 1 to 2 weeks and is excreted in the feces for several weeks or longer after administration . Consequently, the vaccine virus can be transmitted to contacts, resulting in their immunization . However, in rare cases vaccine-associated paralytic poliomyelitis (VAPP) can occur in these contacts as well as in those who are vaccinated .<br\/>"},"9":{"id":"472680-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>do not administer parentally<\/li><li>remove the protective cap off the Dispette(R); squeeze the Dispette(R) to expel the contents into the vaccinee's mouth<\/li><\/ul>"},"13":{"id":"472680-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid close contact with immunosuppressed individuals for 4 to 6 weeks after vaccination.<\/li><li>Tell patient to avoid other vaccines during the polio vaccination series, unless approved by healthcare professional.<\/li><li>This drug may cause fever.<\/li><li>Patient should not have IM injections, especially antibiotics, for up to 60 days after vaccination, as this increases patient risk of developing paralytic poliomyelitis.<\/li><\/ul>"}}}